No Data
No Data
Express News | Cellares, The First Integrated Development And Manufacturing Organization (IDMO), Has Concluded The Technology Adoption Program (TAP) On Its Automated Cell Therapy Manufacturing Cell Shuttle For Resecabtagene Autoleucel, (Rese-cel, Previously Known As...
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle Platform
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
Cabaletta Bio's Promising Clinical Progress and Strong Buy Rating by Douglas Tsao
Cabaletta Bio's Rese-cel Shows Efficacy in Clinical Studies
Unlock the Full List